Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct‐acting antiviral therapy

2019 ◽  
Vol 91 (7) ◽  
pp. 1307-1312 ◽  
Author(s):  
Fred Poordad ◽  
Michael Bennett ◽  
Thomas E. Sepe ◽  
Eric Cohen ◽  
Robert W. Reindollar ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure

Hepatology ◽  
2018 ◽  
Vol 67 (4) ◽  
pp. 1253-1260 ◽  
Author(s):  
Fred Poordad ◽  
Stanislas Pol ◽  
Armen Asatryan ◽  
Maria Buti ◽  
David Shaw ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Failure ◽  
Antiviral Treatment ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Direct Acting Antiviral ◽  
Direct Acting

The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype

2017 ◽  
Vol 20 (1) ◽  
pp. e12803 ◽  
Author(s):  
Alexandra Frey ◽  
Katja Piras-Straub ◽  
Andreas Walker ◽  
Jörg Timm ◽  
Guido Gerken ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Virus Genotype ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment

Hepatology ◽  
2017 ◽  
Vol 66 (2) ◽  
pp. 389-397 ◽  
Author(s):  
Fred Poordad ◽  
Franco Felizarta ◽  
Armen Asatryan ◽  
Mark S. Sulkowski ◽  
Robert W. Reindollar ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Treatment ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Direct Acting Antiviral ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document